Thyroid Cancer Supportive Care Protocol

Thyroid cancer is cancer that develops in the thyroid gland, a butterfly-shaped gland in the neck that produces hormones regulating metabolism. Thyroid cancer is one of the most treatable cancers, with excellent survival rates, especially for differentiated types (papillary and follicular).

TYPES OF THYROID CANCER:

•Papillary (80-85%): Most common; excellent prognosis

•Follicular (10-15%): Good prognosis

•Medullary (3-5%): Arises from C cells; may be hereditary (MEN2)

•Anaplastic (<2%): Aggressive; older patients

CRITICAL: Thyroid cancer treatment requires specialized medical care. This protocol is SUPPORTIVE ONLY and does not replace standard treatment.

STANDARD TREATMENT:

•Surgery: Thyroidectomy (total or partial)

•Radioactive iodine (RAI): For differentiated cancers after surgery

•Thyroid hormone replacement: Levothyroxine for life; often suppressive dose

•External radiation: For certain cases

•Targeted therapies: For advanced or resistant disease

•Surveillance: Regular imaging and thyroglobulin monitoring

IMPORTANT NOTES:

•Iodine: Avoid excess before RAI treatment; low-iodine diet required

•Soy: May interfere with levothyroxine absorption

•Calcium: May be needed if parathyroids affected by surgery

* Selenium supports thyroid function and may have protective effects.

* Vitamin D deficiency is associated with worse thyroid cancer outcomes.

* Omega-3s and Curcumin provide anti-inflammatory support.

Expected timeline: Thyroid cancer treatment is ongoing. Supplements support overall health. Always discuss supplements with oncology team.

Clinical Perspective

Thyroid Cancer: Types - papillary (80-85%, excellent prognosis), follicular (10-15%, good prognosis), medullary (3-5%, from C cells, may be MEN2-associated), anaplastic (<2%, very poor prognosis, older patients). Risk factors: radiation exposure, family history, iodine deficiency/excess, hereditary syndromes. Staging: TNM system. Treatment: surgery (thyroidectomy), RAI for differentiated cancers, TSH suppression with levothyroxine, targeted therapies for advanced disease.

CRITICAL: Thyroid cancer requires specialized oncological care. Supplements are SUPPORTIVE ONLY. Key considerations: 1) Avoid iodine supplements before RAI (low-iodine diet); 2) Some supplements may interfere with levothyroxine; 3) Discuss all supplements with endocrinologist/oncologist; 4) No supplements have proven anti-cancer effects in clinical trials.

* Selenium (B-grade): Thyroid cofactor; some protective data. Systematic review: (PMID: 28558777). Meta-analysis: (PMID: 25758370). 100-200mcg daily. Don't exceed 400mcg.

* Vitamin D (B-grade): Deficiency associated with worse outcomes. Meta-analysis: (PMID: 28750270). 2000-4000 IU daily. Maintain adequate levels.

* Omega-3 Fatty Acids (C-grade): Anti-inflammatory. Systematic review: (PMID: 27840029). 2-3g EPA+DHA daily.

* Curcumin (C-grade): In vitro anti-cancer effects. Review: (PMID: 25282711). 500-1500mg daily. No clinical trials for thyroid cancer.

* Green Tea (EGCG) (C-grade): Experimental data. Review: (PMID: 26440377). 250-500mg daily.

* Vitamin E (C-grade): Antioxidant. Review: (PMID: 27918887). 400 IU daily.

* B-Complex (C-grade): Energy support. Review: (PMID: 27450775). Daily.

* Magnesium (C-grade): Energy; muscle. Review: (PMID: 28150472). 300-400mg daily.

Assessment targets: Thyroglobulin (tumor marker for differentiated), TSH (suppression target), neck ultrasound, whole body scan if RAI given, calcium/PTH if parathyroid involvement.

Protocol notes: Levothyroxine: TSH suppression goal depends on risk stratification; take on empty stomach, consistent timing. RAI preparation: low-iodine diet 1-2 weeks before; avoid iodine supplements, contrast, seaweed, dairy, certain medications. Calcium/vitamin D: may be needed post-surgery if parathyroids affected; monitor PTH, calcium. Medullary: does not concentrate iodine; RAI not useful; check calcitonin, CEA; genetic testing for RET mutations (MEN2). Recurrence monitoring: thyroglobulin trend most important marker for differentiated; unstimulated and stimulated levels. Long-term: excellent prognosis for most differentiated thyroid cancers; 10-year survival >95% for papillary. Supplement timing: separate from levothyroxine by 4 hours (calcium, iron, antacids). Soy: may affect levothyroxine absorption; take separately. Biotin: can interfere with thyroid lab tests; hold before testing. Pregnancy: thyroid cancer monitoring continues; adjust levothyroxine dose. Quality of life: hypothyroid symptoms, fatigue, weight changes common; address symptoms.

View All Protocols